MorphImmune

Morphimmune is a preclinical biotechnology company focused on developing targeted oncology therapeutics. The company’s proprietary Targeted Effector platform selectively delivers payloads to diseased cells. The targeted approach reduces toxicity and increases the efficacy of known effector molecules, ultimately improving outcomes for patients.

MorphImmune headquartered in United States, North America, operates in the Biotechnology, Life Science, Therapeutics sector. The company focuses on Biotechnology and has secured $771.3M in funding across 24 round(s). With a team of 1-10 employees, MorphImmune is actively contributing to advancements in Biotechnology. Their latest funding round, Venture Round - MorphImmune, raised $15.0M. Discover more about their projects, partnerships, and impact on our platform.